Revvity, Inc. · NYSE:RVTY
Revvity — PerkinElmer — Merger or Acquisition (August 2022)
10 slides from Revvity's merger presentation, Aug 1, 2022
Slide 1: Introducing a High-Growth, High-Margin Life Sciences and Diagnostics Company with Scale
Introducing a High-Growth, High-Margin Life Sciences and Diagnostics Company with Scale August 1, 2022
Slide 2: Accelerating Our Transformation
ACCELERATING OUR TRANSFORMATION • Announces agreement with intention to divest the Analytical, Food, and Enterprise Services businesses to New Mountain Capital for a total consideration of $2.45 billion, including $2.3 billion in cash to be received at closing and $150 million of future contingent c
Slide 3: Creating a Pure Play, Science-First Company
CREATING A PURE PLAY, SCIENCE-FIRST COMPANY OUR JOURNEY Increased Focus on 2019 2021 2023 Life Sciences and Diagnostics % Revenue ~60% ~80% 100% LS & Dx LS & Dx LS & Dx Accelerated Innovation and Capital Deployment Gross Margin ~50%+ ~60%+ A Faster Growing, Higher Margin % Recurring Company with Str
Slide 4: Best-In-Class Portfolio That Is Positioned To Produce Better Customer Outcomes
BEST-IN-CLASS PORTFOLIO THAT IS POSITIONED TO PRODUCE BETTER CUSTOMER OUTCOMES LIFE SCIENCES DIAGNOSTICS ✓ Top-tier pre-clinical research & ✓ Leading solutions in infectious disease & discovery franchise autoimmune markets ✓ Attractive and expanded positions in biologics and cell and gene therapy ~4
Slide 5: Life Sciences: Leading with Innovation to Drive Our Customers' Pre-Clinical Research & Discovery
LIFE SCIENCES: LEADING WITH INNOVATION TO DRIVE OUR CUSTOMERS’ PRE-CLINICAL RESEARCH & DISCOVERY ~$1.3B Best-in-Class Franchise Expected to PORTFOLIO HIGHLIGHTS Grow LDD with Unique Ability to Close the Chasm from Research to Clinic INSTRUMENTS Broad menu of biomarker, flow- ~$0.7B REAGENTS based, c
Slide 6: Diagnostics: Strong Positions In Attractive, High-Growth End-Markets
DIAGNOSTICS: STRONG POSITIONS IN ATTRACTIVE, HIGH-GROWTH END-MARKETS ~$2B Global Portfolio Expected to Grow HSD PORTFOLIO HIGHLIGHTS with Leading Franchises Dedicated to COMPLETE WORKFLOW & SERVICES Advancing Global Health ASSAYS REAGENTS Extensive menu across ~$1.1B IMMUNODX autoimmune, allergy, an
Slide 7: A Clear Vision Centered On Collaborative Discovery
A CLEAR VISION CENTERED ON COLLABORATIVE DISCOVERY WHAT IT MEANS FOR… OUR CUSTOMERS OUR EMPLOYEES Increased Focus and Leadership Ability to Scale, Driving Centered on Customer Value Core Growth Areas Accelerating Innovation Greater Opportunity to with a Solutions Develop and Maintain Driven Mindset
Slide 8: A Stronger Outlook For The Future With Significant Scale
A STRONGER OUTLOOK FOR THE FUTURE WITH SIGNIFICANT SCALE Historical Financial Outlook ‘24-‘26 Outlook* Organic Growth HSD 10%+ Recurring Revenue 75% ~80% Operating Margins 26%+ 30%+ Operating Margin Expansion 50-75 75-100 bps / year bps / year Adj EPS Growth >10% 13-15% SIGNIFICANT CAPITAL DEPLOYMEN
Slide 9: Growth & Margin Profile Now Aligned With High-Value LS Dx Peers
GROWTH & MARGIN PROFILE NOW ALIGNED WITH HIGH-VALUE LS DX PEERS FY 2023e Revenue Growth1 FY 2023e adj. EV / EBITDA Multiple1 12% 10%+ 25x 8%+ 6% $2.3B $3B+ 2023e Avg. 20x 2023e Revenue Revenue 19x 2 Core Tools Legacy PKI PKI LSDX LSDX Peers 3 Median FY 2022e Operating Profit Margin1 30%+ 25% 26%+ 26
Slide 10: Key Takeaways From Today
KEY TAKEAWAYS FROM TODAY DELIVERING VALUE FOR ATTRACTIVE END-MARKETS OUR SHAREHOLDERS, WITH SIGNIFICANT SCALE CUSTOMERS, AND EMPLOYEES HIGHER-GROWTH, POSITIONS THE HIGHER-MARGIN WITH COMPANY INTO A NEW SIGNIFICANT RECURRING INDUSTRY COHORT REVENUES & SCALE 10